EUVIMEDEUVIMED entdecken
Übersichtsarbeit

New Immunosuppressants in Clinical Trial

Vivian C McAlister

Current Drug Target -Cardiovascular & Hematological Disorders · 2002

DOI: 10.2174/1568006023337510 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Drug Target -Cardiovascular & Hematological Disorders, 2002. Verfasst von Vivian C McAlister. Beteiligte Einrichtung: Department of Surgery, University of Western Ontario, London, Ontario, Canada. vmcalist@uwo.ca. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemical immunosuppression developed at the beginning of clinical transplantation remains the basis of immunosuppressive protocols used today. Clinical trials of new agents focus on the incremental improvement in one of four areas of immunotherapy: induction, basic maintenance, adjuvant and steroid therapy. Induction immunotherapy developments include the use of humanized antibodies, specific targets (basiliximab, daclizumab) and lymphocyte depletion (anti-thymocyte globulin, campath-1H). Promising results from pilot trials allow for subsequent low dose maintenance monotherapy. New inhibitors of calcineurin isoforms (ISATx247) may disassociate the anti-rejection effect from the toxicity of conventional calcineurin inhibitors. Revived investigation of older anti-proliferative or anti-metabolite drugs (rapamycin, mycophenolic acid, leflunomide) show promise in preventing B-cell responses and reducing chronic rejection but development of derivatives (everolimus, mycophenolate mofetil, ERL 080, MNA 279, MNA 715) may have a stronger commercial than experimental basis. Trials of steroid immunotherapy have focused on steroid elimination but trial of newer locally active steroids may be beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsClinical Trials as TopicHumansImmunosuppressive Agents

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Department of Surgery, University of Western Ontario, London, Ontario, Canada. vmcalist@uwo.ca

Zitieren

APA

McAlister, V. C. (2002). New Immunosuppressants in Clinical Trial. Current Drug Target -Cardiovascular & Hematological Disorders. https://doi.org/10.2174/1568006023337510

Vancouver

McAlister VC. New Immunosuppressants in Clinical Trial. Current Drug Target -Cardiovascular & Hematological Disorders. 2002. doi:10.2174/1568006023337510

BibTeX
@article{McAlister2002,
  author = {McAlister, Vivian C},
  title = {New Immunosuppressants in Clinical Trial},
  journal = {Current Drug Target -Cardiovascular & Hematological Disorders},
  year = {2002},
  doi = {10.2174/1568006023337510}
}
Kostenlos starten →